Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development

The molecular chaperone Hsp90 is one component of a highly complex and interactive cellular proteostasis network (PN) that participates in protein folding, directs misfolded and damaged proteins for destruction, and participates in regulating cellular transcriptional responses to environmental stress, thus promoting cell and organismal survival. Over the last 20 years, it has become clear that various disease states, including cancer, neurodegeneration, metabolic disorders, and infection by diverse microbes, impact the PN. Among PN components, Hsp90 was among the first to be pharmacologically targeted with small molecules. While the number of Hsp90 inhibitors described in the literature has dramatically increased since the first such small molecule was described in 1994, it has become increasingly apparent that not all of these agents have been sufficiently validated for specificity, mechanism of action, and lack of off-target effects. Given the less than expected activity of Hsp90 inhibitors in cancer-related human clinical trials, a re-evaluation of potentially confounding off-target effects, as well as confidence in target specificity and mechanism of action, is warranted. In this commentary, we provide feasible approaches to achieve these goals and we discuss additional considerations to improve the clinical efficacy of Hsp90 inhibitors in treating cancer and other diseases.

[1]  Bonnie Berger,et al.  A Quantitative Chaperone Interaction Network Reveals the Architecture of Cellular Protein Homeostasis Pathways , 2014, Cell.

[2]  T. Ulmer,et al.  Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression , 2016, Oncogene.

[3]  R. Morimoto,et al.  Molecular chaperones as HSF1-specific transcriptional repressors. , 1998, Genes & development.

[4]  Christian von Mering,et al.  Cell-wide analysis of protein thermal unfolding reveals determinants of thermostability , 2017, Science.

[5]  James B. Mitchell,et al.  Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs. , 2010, Free radical biology & medicine.

[6]  Karin Sadoul,et al.  Heat-shock factor 1 controls genome-wide acetylation in heat-shocked cells. , 2009, Molecular biology of the cell.

[7]  D. Bourboulia,et al.  Structural and functional basis of protein phosphatase 5 substrate specificity , 2016, Proceedings of the National Academy of Sciences.

[8]  A. Maxwell The interaction between coumarin drugs and DNA gyrase , 1993, Molecular microbiology.

[9]  Gabriela Chiosis,et al.  Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. , 2006, Journal of medicinal chemistry.

[10]  R. Matts,et al.  Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action. , 2009, Current topics in medicinal chemistry.

[11]  C. Erlichman,et al.  Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. , 2006, Cancer research.

[12]  D. Cyr,et al.  Protein quality control: U-box-containing E3 ubiquitin ligases join the fold. , 2002, Trends in biochemical sciences.

[13]  M. Egorin,et al.  Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts , 2004, Cancer Chemotherapy and Pharmacology.

[14]  J. Berger,et al.  Structural basis for topoisomerase VI inhibition by the anti-Hsp90 drug radicicol , 2006, Nucleic acids research.

[15]  C. Moody,et al.  Learning from nature: advances in geldanamycin- and radicicol-based inhibitors of Hsp90. , 2013, The Journal of organic chemistry.

[16]  D. Agard,et al.  Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase , 2016, Science.

[17]  N. Rosen,et al.  Development of purine-scaffold small molecule inhibitors of Hsp90. , 2003, Current cancer drug targets.

[18]  S. Lindquist,et al.  Inhibiting the transcription factor HSF1 as an anticancer strategy , 2009 .

[19]  R. Condé,et al.  Modulation of Hsf1 activity by novobiocin and geldanamycin. , 2009, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[20]  H. Edenberg Novobiocin inhibition of simian virus 40 DNA replication , 1980, Nature.

[21]  C. K. Pearson,et al.  Effect of drugs on deoxyribonucleic acid synthesis in isolated mammalian cell nuclei. Comparison with partially purified deoxyribonucleic acid polymerases. , 1979, Biochemical Journal.

[22]  B. Blagg,et al.  Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects. , 2016, Advances in cancer research.

[23]  N. Rosen,et al.  Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion , 2011, Proceedings of the National Academy of Sciences.

[24]  L. Sistonen,et al.  Regulation of HSF1 function in the heat stress response: implications in aging and disease. , 2011, Annual review of biochemistry.

[25]  K. M. Popov,et al.  An Essential Role of Glu-243 and His-239 in the Phosphotransfer Reaction Catalyzed by Pyruvate Dehydrogenase Kinase* , 2001, The Journal of Biological Chemistry.

[26]  G. Drewes,et al.  Tracking cancer drugs in living cells by thermal profiling of the proteome , 2014, Science.

[27]  D. Gewirth Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future. , 2016, Current topics in medicinal chemistry.

[28]  C. Nicchitta,et al.  Structure of the N-terminal Domain of GRP94 , 2003, Journal of Biological Chemistry.

[29]  D. Mok,et al.  Modulation of Chaperone Function and Cochaperone Interaction by Novobiocin in the C-terminal Domain of Hsp90 , 2006, Journal of Biological Chemistry.

[30]  M. Rane,et al.  Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex. , 2009, Free radical biology & medicine.

[31]  C. Nicchitta,et al.  Development of a Grp94 inhibitor. , 2012, Journal of the American Chemical Society.

[32]  G. Giaccone,et al.  Targeting the dynamic HSP90 complex in cancer , 2010, Nature Reviews Cancer.

[33]  L. Pearl,et al.  Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.

[34]  S. Filipek,et al.  Mutations that increase both Hsp90 ATPase activity in vitro and Hsp90 drug resistance in vivo. , 2010, Biochimica et biophysica acta.

[35]  Gabriela Chiosis,et al.  Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. , 2006, Journal of medicinal chemistry.

[36]  L. Neckers,et al.  Post-translational modifications of Hsp90 and their contributions to chaperone regulation. , 2012, Biochimica et biophysica acta.

[37]  P. Doležel,et al.  N-acetylcysteine prevents the geldanamycin cytotoxicity by forming geldanamycin-N-acetylcysteine adduct. , 2014, Chemico-biological interactions.

[38]  John G. Doench,et al.  Ophir Shalem Genome-Scale CRISPR-Cas 9 Knockout Screening in Human Cells , 2014 .

[39]  Saijuan Chen,et al.  Vibsanin B Preferentially Targets HSP90β, Inhibits Interstitial Leukocyte Migration, and Ameliorates Experimental Autoimmune Encephalomyelitis , 2015, The Journal of Immunology.

[40]  Corey Nislow,et al.  Recent advances and method development for drug target identification. , 2010, Trends in pharmacological sciences.

[41]  T. Gasiewicz,et al.  (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. , 2009, Biochemistry.

[42]  L. Neckers,et al.  The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone* , 2000, The Journal of Biological Chemistry.

[43]  David Z. D'Argenio,et al.  Physiologically-Based Pharmacokinetics and Molecular Pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and Its Active Metabolite in Tumor-Bearing Mice , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[44]  H. Feng,et al.  Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. , 2001, Blood.

[45]  S. Lindquist,et al.  Using the heat-shock response to discover anticancer compounds that target protein homeostasis. , 2011, ACS chemical biology.

[46]  R. Dobrowsky,et al.  Heat Shock Protein 70 Is Necessary to Improve Mitochondrial Bioenergetics and Reverse Diabetic Sensory Neuropathy following KU-32 Therapy , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[47]  P. Workman,et al.  Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. , 2008, Cancer research.

[48]  L. Pearl,et al.  Structural basis of the radicicol resistance displayed by a fungal hsp90. , 2009, ACS chemical biology.

[49]  Philip F. Hughes,et al.  A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo. , 2017, ACS chemical biology.

[50]  A. Dixit,et al.  A systematic protocol for the characterization of Hsp90 modulators. , 2011, Bioorganic & medicinal chemistry.

[51]  Philip F. Hughes,et al.  The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding , 2016, Nature Communications.

[52]  D. Picard Preface to Hsp90. , 2012, Biochimica et biophysica acta.

[53]  S. Plymate,et al.  Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. , 2016, Cancer research.

[54]  J. Buchner,et al.  Analysis of chaperone function using citrate synthase as nonnative substrate protein. , 1998, Methods in enzymology.

[55]  Yao Wang,et al.  Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors. , 2017, Chemistry.

[56]  M. Bogyo,et al.  Target deconvolution techniques in modern phenotypic profiling. , 2013, Current opinion in chemical biology.

[57]  L. Neckers,et al.  Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis , 2013, Proceedings of the National Academy of Sciences.

[58]  S. Larson,et al.  The epichaperome is an integrated chaperome network that facilitates tumour survival , 2016, Nature.

[59]  W. A. A. Glance Diverse , 2002, Encyclopedia of the UN Sustainable Development Goals.

[60]  S. Kasibhatla,et al.  EC144 is a potent inhibitor of the heat shock protein 90. , 2012, Journal of medicinal chemistry.

[61]  J. Markley,et al.  Dynamical Structures of Hsp70 and Hsp70-Hsp40 Complexes. , 2016, Structure.

[62]  Daniel Martinez Molina,et al.  The Cellular Thermal Shift Assay: A Novel Biophysical Assay for In Situ Drug Target Engagement and Mechanistic Biomarker Studies. , 2016, Annual review of pharmacology and toxicology.

[63]  Briana Foley,et al.  Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. , 2010, Chemistry & biology.

[64]  D. Bolon,et al.  Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors. , 2013 .

[65]  Timothy A. J. Haystead,et al.  The Amino-terminal Domain of Heat Shock Protein 90 (hsp90) That Binds Geldanamycin Is an ATP/ADP Switch Domain That Regulates hsp90 Conformation* , 1997, The Journal of Biological Chemistry.

[66]  S. Gambhir,et al.  Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects , 2012, Proceedings of the National Academy of Sciences.

[67]  L. Neckers,et al.  Hsp90 in Cancer: Transcriptional Roles in the Nucleus. , 2016, Advances in cancer research.

[68]  D. Thiele,et al.  Modulation of Heat Shock Transcription Factor 1 as a Therapeutic Target for Small Molecule Intervention in Neurodegenerative Disease , 2010, PLoS biology.

[69]  P. Brown,et al.  Drug target validation and identification of secondary drug target effects using DNA microarrays , 1998, Nature Medicine.

[70]  C. Turck,et al.  Inhibition of branched-chain alpha-keto acid dehydrogenase kinase and Sln1 yeast histidine kinase by the antifungal antibiotic radicicol. , 2002, Molecular pharmacology.

[71]  D. Harrison,et al.  Geldanamycin Leads to Superoxide Formation by Enzymatic and Non-enzymatic Redox Cycling , 2002, The Journal of Biological Chemistry.

[72]  R. Paro,et al.  Hsp90@chromatin.nucleus: an emerging hub of a networker. , 2013, Trends in cell biology.

[73]  S. Landas,et al.  c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells , 2015, Cell reports.

[74]  B. Freeman,et al.  p23/Sba1p Protects against Hsp90 Inhibitors Independently of Its Intrinsic Chaperone Activity , 2008, Molecular and Cellular Biology.

[75]  J. Onuchic,et al.  Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90β , 2016, Proceedings of the National Academy of Sciences of the United States of America.

[76]  L. Pearl,et al.  NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. , 2008, Cancer research.

[77]  M. Gerstein,et al.  Diverse Cellular Functions of the Hsp90 Molecular Chaperone Uncovered Using Systems Approaches , 2007, Cell.

[78]  Philip F. Hughes,et al.  A highly selective Hsp90 affinity chromatography resin with a cleavable linker. , 2012, Bioorganic & medicinal chemistry.

[79]  L. Neckers,et al.  Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[80]  B. Blagg,et al.  Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. , 2013, Assay and drug development technologies.

[81]  Julian Blagg,et al.  Chemical biology approaches to target validation in cancer. , 2014, Current opinion in pharmacology.

[82]  M. Vidal,et al.  HSP90 Shapes the Consequences of Human Genetic Variation , 2017, Cell.

[83]  Ahmad S. Khalil,et al.  Dynamic control of Hsf1 during heat shock by a chaperone switch and phosphorylation , 2016, eLife.

[84]  Min Huang,et al.  Correction to "Discovery and Optimization of 4,5-Diarylisoxazoles as Potent Dual Inhibitors of Pyruvate Dehydrogenase Kinase and Heat Shock Protein 90". , 2014, Journal of medicinal chemistry.

[85]  S. Lindquist,et al.  Reduced levels of hsp90 compromise steroid receptor action in vivo , 1990, Nature.

[86]  Neville E. Sanjana,et al.  High-throughput functional genomics using CRISPR–Cas9 , 2015, Nature Reviews Genetics.

[87]  R. Matts,et al.  Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. , 2004, Biochemistry.

[88]  K. Kohn,et al.  Heat shock protein 90α (HSP90α), a substrate and chaperone of DNA-PK necessary for the apoptotic response , 2012, Proceedings of the National Academy of Sciences.

[89]  L. Neckers,et al.  Polyubiquitination and Proteasomal Degradation of the p185c-erbB-2 Receptor Protein-tyrosine Kinase Induced by Geldanamycin* , 1996, The Journal of Biological Chemistry.

[90]  Jun Li,et al.  Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. , 2007, Structure.

[91]  L. Pearl,et al.  Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone , 1997, Cell.

[92]  S. Ohkubo,et al.  TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models , 2014, Molecular Cancer Therapeutics.

[93]  S. Lindquist,et al.  Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of Carcinogenesis , 2007, Cell.

[94]  P. Gruss,et al.  Mice lacking HSP90beta fail to develop a placental labyrinth. , 2000, Development.

[95]  M. Mayer,et al.  Molecular mechanism of thermosensory function of human heat shock transcription factor Hsf1 , 2016, eLife.

[96]  Anshuman Dixit,et al.  Elucidation of the Hsp90 C-terminal inhibitor binding site. , 2011, ACS chemical biology.

[97]  P. Forterre,et al.  Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol , 2005, Nucleic acids research.

[98]  W. Linehan,et al.  Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma , 2015, Hepatology.

[99]  W. Pratt,et al.  Evidence for a Mechanism of Repression of Heat Shock Factor 1 Transcriptional Activity by a Multichaperone Complex* , 2001, The Journal of Biological Chemistry.

[100]  Min Huang,et al.  Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90. , 2014, Journal of medicinal chemistry.

[101]  R. Voellmy,et al.  Repression of Heat Shock Transcription Factor HSF1 Activation by HSP90 (HSP90 Complex) that Forms a Stress-Sensitive Complex with HSF1 , 1998, Cell.

[102]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[103]  K. Johnsson,et al.  A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis. , 2011, Nature chemical biology.

[104]  C. Rudin,et al.  A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species , 2015, Cell reports.

[105]  G. Terstappen,et al.  Target deconvolution strategies in drug discovery , 2007, Nature Reviews Drug Discovery.

[106]  Daozhen Chen,et al.  Synthesis of (131)I-labeled-[(131)I]iodo-17-allylamino-17-demethoxy geldanamycin ([(131)I]iodo-17-AAG) and its biodistribution in mice. , 2007, Cancer biotherapy & radiopharmaceuticals.

[107]  G. Superti-Furga,et al.  Target profiling of small molecules by chemical proteomics. , 2009, Nature chemical biology.

[108]  Marc L. Mendillo,et al.  HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models , 2014, Proceedings of the National Academy of Sciences.

[109]  G. Leo,et al.  Biotransformation of Geldanamycin and 17-Allylamino-17-Demethoxygeldanamycin by Human Liver Microsomes: Reductive versus Oxidative Metabolism and Implications , 2007, Drug Metabolism and Disposition.

[110]  Marc L. Mendillo,et al.  HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers , 2012, Cell.

[111]  B. Blagg,et al.  Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail. , 2016, ACS medicinal chemistry letters.

[112]  S. Lindquist,et al.  Protein homeostasis and the phenotypic manifestation of genetic diversity: principles and mechanisms. , 2010, Annual review of genetics.

[113]  L. Neckers,et al.  Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. , 2000, Journal of the National Cancer Institute.

[114]  Adnan Ali,et al.  Multiple Components of the HSP90 Chaperone Complex Function in Regulation of Heat Shock Factor 1 In Vivo , 1999, Molecular and Cellular Biology.

[115]  X. Barril,et al.  Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. , 2004, Chemistry & biology.

[116]  T. Yao,et al.  HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. , 2007, Genes & development.

[117]  Neal Rosen,et al.  Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.

[118]  M. Inouye,et al.  GHKL, an emergent ATPase/kinase superfamily. , 2000, Trends in biochemical sciences.

[119]  S. Lindquist,et al.  hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures , 1989, Molecular and cellular biology.

[120]  B. Blagg,et al.  High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase. , 2007, Bioorganic & medicinal chemistry.

[121]  Mike Wood,et al.  4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.

[122]  L. Zitvogel,et al.  Reply: The complement system is also important in immunogenic cell death , 2016, Nature Reviews Immunology.

[123]  M. Graner HSP90 and Immune Modulation in Cancer. , 2016, Advances in cancer research.

[124]  S. Landas,et al.  Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors , 2016, Cell reports.

[125]  L. Pearl,et al.  Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. , 2010, Molecular cell.

[126]  W. Stetler-Stevenson,et al.  Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors. , 2014, Molecular cell.

[127]  L. Whitesell,et al.  Expression of a unique drug-resistant Hsp90 ortholog by the nematode Caenorhabditis elegans , 2003, Cell stress & chaperones.

[128]  Stefan Pinkert,et al.  Interplay of Acetyltransferase EP300 and the Proteasome System in Regulating Heat Shock Transcription Factor 1 , 2014, Cell.

[129]  R. Paro,et al.  Hsp90 Globally Targets Paused RNA Polymerase to Regulate Gene Expression in Response to Environmental Stimuli , 2012, Cell.

[130]  S. Larson,et al.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. , 2011, Nature chemical biology.

[131]  Michael I. Jordan,et al.  Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[132]  B. Seed,et al.  Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability , 2001, Nature Cell Biology.

[133]  L. Neckers,et al.  Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. , 2006, ACS chemical biology.

[134]  B. Blagg,et al.  Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells , 2011, BMC Cancer.

[135]  L. Neckers,et al.  An Hsp90 co-chaperone protein in yeast is functionally replaced by site-specific posttranslational modification in humans , 2017, Nature Communications.

[136]  L. Neckers,et al.  Hsp 90 Molecular Chaperone Inhibitors : Are We There Yet ? , 2011 .

[137]  Paul Workman,et al.  Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? , 2012, Clinical Cancer Research.

[138]  D. Proia,et al.  Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy , 2015, Cancer Immunology Research.

[139]  C. Nicchitta,et al.  Development of a Grp 94 inhibitor , 2012 .

[140]  Adnan Ali,et al.  HSP90 Interacts with and Regulates the Activity of Heat Shock Factor 1 in Xenopus Oocytes , 1998, Molecular and Cellular Biology.

[141]  S. Horinouchi,et al.  Radicicol Binds and Inhibits Mammalian ATP Citrate Lyase* , 2000, The Journal of Biological Chemistry.